ArticleThe Lancet regional health. Europe2026

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study.

Henrik Svanström et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.